Enveric Biosciences Inc vs Energy Select Sector SPDR Fund — how do they compare? Enveric Biosciences Inc trades at $1.38 (market cap $5.32M), while Energy Select Sector SPDR Fund trades at $57.2. The key difference: Energy Select Sector SPDR Fund is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | XLE | |
|---|---|---|
Market Cap | $5.32M | — |
Sector | Health | — |
52-Week High | $17.40 | $62.57 |
52-Week Low | $1.28 | $42.12 |
Enterprise Value | $408.82K | — |
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
XLE, the Energy Select Sector SPDR ETF, trades at $56.95, showing no daily change. Technical indicators signal a bullish trend with moving averages supporting upside momentum, though the RSI suggests potential overbought conditions near-term. The ETF has been a top performer in 2026, gaining 21% year-to-date as energy sector earnings drive growth. A dividend of $0.38 is scheduled for June 2026.
Outlook remains positive given strong sector earnings and oil price support, but risks include volatility from geopolitical tensions and fluctuating crude prices. Investor sentiment is buoyed by data center energy demand and disciplined capital expenditure, yet analyst views are mixed pending clearer long-term signals.
Trailing returns across standard periods
Latest headlines on both assets
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →